All articles tagged: Gastro-esophageal reflux disease without esophagitis (K21.9)

For patients with refractory gastroesophageal reflux disease (GERD), those receiving antireflux mucosectomy (ARMS) have a greater improvement in the GERD questionnaire (GERDQ) score, according to a study published online June 12 in Surgical Endoscopy.Ah Young Lee, M.D., Ph.D., from Cha University in Seoul, South Korea, and colleagues

Gastroesophageal reflux disease (GERD) is associated with an increased incidence of atrial fibrillation, according to a study published online June 2 in Frontiers in Cardiovascular Medicine.Lei Wang and Yi Wei Lu, from the Aerospace Center Hospital in Beijing, and colleagues assessed GERD’s role as a potential contributing factor i

Gastroesophageal reflux disease (GERD) causally and positively influences rheumatoid arthritis (RA), but RA has no significant influence on GERD, according to a study published online Dec. 13 in Frontiers in Genetics.Haifan Wang, from The Second Affiliated Hospital of Xi'an Jiaotong University in China, and colleagues examined the bi

For preschool-aged children, pH-multichannel intraluminal impedance (MII) monitoring is useful for diagnosing gastroesophageal reflux disease (GERD)-related wheezing, according to a study published online Nov. 29 in Diagnostics.Ivan Pavic, M.D., from Children's Hospital Zagreb in Croatia, and colleagues examined the diagnostic value of

For patients who have undergone bariatric surgery for gastroesophageal reflux disease (GERD), revision surgery is common and is mainly with a Roux-en-Y gastric bypass (RYGB), according to a study published online Oct. 31 in Surgical Endoscopy.Sarah MacVicar, M.D., from the University of Alberta Hospital in Edmonton, Canada, and colleague

A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday. The weight-loss drug Zepbound contains the same active ingredient, tirzepatide, as the diabetes drug Mounjaro.Zepbound works by activating hormone receptors in the body to reduce appetite

The U.S. Food and Drug Administration has approved Voquezna (vonoprazan), a novel potassium-competitive acid blocker, as a new treatment for adults for with all grades of erosive esophagitis or erosive gastroesophageal reflux disease (GERD).The approval is based on the results of the PHALCON-EE phase 3 trial, in which Voquezna 20 mg met the prim

Antireflux mucosal ablation (ARMA) cuts short-term gastroesophageal reflux disease (GERD) symptoms in two-thirds of patients undergoing the endoscopic treatment, according to a study published online Oct. 3 in the Journal of Gastroenterology and Hepatology. Yuto Shimamura, M.D., from Showa University in Tokyo, and colleagues ev